![Stephen Yoo](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Stephen Yoo
Vorstandsvorsitzender bei Anjarium Biosciences AG
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
David Stump | M | 74 | 9 Jahre | |
Argeris Karabelas | M | 71 | 9 Jahre | |
Curran Simpson | M | 62 | 9 Jahre | |
Daniel Tassé | M | 64 | 8 Jahre | |
Ram Palanki | M | 48 | 6 Jahre | |
Alexandra Glucksmann | M | 65 | 6 Jahre | |
Shiva G. Fritsch | F | - | 7 Jahre | |
Patrick Christmas | M | 53 | 8 Jahre | |
Douglas Fambrough | M | 55 |
Anjarium Biosciences AG
![]() Anjarium Biosciences AG BiotechnologyHealth Technology Anjarium Biosciences AG is a Swiss company that focuses on creating a new class of non-viral gene therapies to tackle genetic diseases throughout a patient's lifetime. The company is based in Schlieren, Switzerland. The company's versatile platform leverages breakthrough science and expertise at the interface of genetic medicine, synthetic biology, and nanoparticle engineering to generate a pipeline of advanced gene therapies with unique competitive advantages over current viral-vector based gene therapies. Anjarium's investors include leading international and strategic investors such as Abingworth, Gimv, Omega Funds, Pfizer Ventures, and Surveyor Capital. The company was founded by Joël de Beer, and Stephen Yoo has been the CEO of the company since 2022. | 2 Jahre |
Dina Chaya | M | 52 |
Anjarium Biosciences AG
![]() Anjarium Biosciences AG BiotechnologyHealth Technology Anjarium Biosciences AG is a Swiss company that focuses on creating a new class of non-viral gene therapies to tackle genetic diseases throughout a patient's lifetime. The company is based in Schlieren, Switzerland. The company's versatile platform leverages breakthrough science and expertise at the interface of genetic medicine, synthetic biology, and nanoparticle engineering to generate a pipeline of advanced gene therapies with unique competitive advantages over current viral-vector based gene therapies. Anjarium's investors include leading international and strategic investors such as Abingworth, Gimv, Omega Funds, Pfizer Ventures, and Surveyor Capital. The company was founded by Joël de Beer, and Stephen Yoo has been the CEO of the company since 2022. | 3 Jahre |
Olivier Danos | M | 66 | 7 Jahre | |
Bali Muralidhar | M | 44 |
Anjarium Biosciences AG
![]() Anjarium Biosciences AG BiotechnologyHealth Technology Anjarium Biosciences AG is a Swiss company that focuses on creating a new class of non-viral gene therapies to tackle genetic diseases throughout a patient's lifetime. The company is based in Schlieren, Switzerland. The company's versatile platform leverages breakthrough science and expertise at the interface of genetic medicine, synthetic biology, and nanoparticle engineering to generate a pipeline of advanced gene therapies with unique competitive advantages over current viral-vector based gene therapies. Anjarium's investors include leading international and strategic investors such as Abingworth, Gimv, Omega Funds, Pfizer Ventures, and Surveyor Capital. The company was founded by Joël de Beer, and Stephen Yoo has been the CEO of the company since 2022. | - |
Jerome W. Jackson | M | - | 9 Jahre | |
Gaurav D. Shah | M | 49 |
Anjarium Biosciences AG
![]() Anjarium Biosciences AG BiotechnologyHealth Technology Anjarium Biosciences AG is a Swiss company that focuses on creating a new class of non-viral gene therapies to tackle genetic diseases throughout a patient's lifetime. The company is based in Schlieren, Switzerland. The company's versatile platform leverages breakthrough science and expertise at the interface of genetic medicine, synthetic biology, and nanoparticle engineering to generate a pipeline of advanced gene therapies with unique competitive advantages over current viral-vector based gene therapies. Anjarium's investors include leading international and strategic investors such as Abingworth, Gimv, Omega Funds, Pfizer Ventures, and Surveyor Capital. The company was founded by Joël de Beer, and Stephen Yoo has been the CEO of the company since 2022. | 2 Jahre |
Samantha Vieira | F | - |
Anjarium Biosciences AG
![]() Anjarium Biosciences AG BiotechnologyHealth Technology Anjarium Biosciences AG is a Swiss company that focuses on creating a new class of non-viral gene therapies to tackle genetic diseases throughout a patient's lifetime. The company is based in Schlieren, Switzerland. The company's versatile platform leverages breakthrough science and expertise at the interface of genetic medicine, synthetic biology, and nanoparticle engineering to generate a pipeline of advanced gene therapies with unique competitive advantages over current viral-vector based gene therapies. Anjarium's investors include leading international and strategic investors such as Abingworth, Gimv, Omega Funds, Pfizer Ventures, and Surveyor Capital. The company was founded by Joël de Beer, and Stephen Yoo has been the CEO of the company since 2022. | 2 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Luke Beshar | M | 65 | 6 Jahre | |
Edgar Engleman | M | 78 | 1 Jahre | |
Camille Samuels | F | 52 | 1 Jahre | |
Daniel Abdun-Nabi | M | 69 | 6 Jahre | |
Sara Garon Berl | F | - | 8 Jahre | |
Benjamin Auspitz | M | 51 | - | |
Michael C. Gelman | M | - | - | |
John Daniel Kiser | M | - | - | |
Faraz Ali | M | 51 | 2 Jahre | |
Lynne McGrath | M | 69 | 3 Jahre | |
Rickey Reinhardt | M | - | - |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Vereinigte Staaten | 21 | 80,77% |
Schweiz | 5 | 19,23% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Stephen Yoo
- Persönliches Netzwerk